PMN310 is uniquely designed to selectively target toxic oligomers of amyloid-beta, which we believe is a key differentiator ... ProMIS continues to advance its Aβ vaccine program in AD based on its ...

PMN310 is uniquely designed to selectively target toxic oligomers of amyloid-beta, which we believe is ... Aβ vaccine program in AD based on its oligomer target epitope(s). ProMIS will present ...

PMN310 is uniquely designed to selectively target toxic oligomers of amyloid-beta, which we believe is ... Aß vaccine program in AD based on its oligomer target epitope(s). ProMIS will present ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

“It stops the amyloid beta oligomer buildup, and also stops the consequences of neuroinflammation, which causes a lot of damage in the brain. So, the drug is very powerful on two ...

"It stops the amyloid beta oligomer buildup, and also stops the consequences of neuroinflammation, which causes a lot of damage in the brain. So, the drug is very powerful on two levels ...

A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...